Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Outstrips Viatris’ Pentasa Action Date With First ANDA Approval

Analyst Forecasts Launch Could Add Up To $70m In Revenues

Executive Summary

Sun Pharma has scooped a first ANDA approval for a rival to Takeda’s mesalamine-containing brand Pentasa, with Viatris making clear recently that it was eyeing a first-time generic launch for the gastrointestinal drug.

You may also be interested in...



Zydus Looks To Revlimid Opportunity, Pivots To Multivariant COVID-19 Vaccine

Zydus is looking to launch a Revlimid generic in the second wave while an opportunity might soon emerge from Takeda’s Pentasa. It is also pivoting to a multivariant version of its plasmid DNA vaccine against COVID-19, ZyCoV-D, after the original didn’t receive an encouraging response.

Zydus Pivots To Multivariant COVID-19 Vaccine, Looks To Revlimid Opportunity

Zydus is pivoting to a multivariant version of its plasmid DNA vaccine against COVID-19, ZyCoV-D, after the original didn’t receive an encouraging response. It also looks to launch a Revlimid generic in the second wave while an opportunity might soon emerge from Takeda’s Pentasa.

Viatris Will Not Rule Out Symbicort In 2022 As Trial Looms

Facing down a key patent infringement trial beginning on 19 May, Viatris is continuing to eye an opportunity to launch its Breyna generic version of AstraZeneca’s Symbicort before patent expiry in 2023.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel